| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
4
| Cotter Sara (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.39, valued at
$139k
|
|
| 07/27/2023 |
3
| Cotter Sara (Director) has filed a Form 3 on Invivyd, Inc. |
| 07/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS WALTHAM, Mass., JULY 27, 2023 — Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development. “Ms. Cotter's comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital markets expertise, make her an excellent addition to our board of directors,” said Dave Hering, Chief Executive Officer of Invivyd. “Her keen industry insights and impressive accomplishments in drug development and healthcare investing will be invaluable to Invivyd a..." |
|
| 06/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
4
| MCGUIRE TERRANCE (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
4
| Heyman Tomas J. (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
4
| WYZGA MICHAEL S (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
4
| Lindenboom Christine (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 29,589 options to buy
@ $1.7, valued at
$50.3k
|
|
| 05/25/2023 |
4
| MEANWELL CLIVE (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
4
| Berry Tamsin (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
4
| Elia Marc (Director) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.7, valued at
$85k
|
|
| 05/25/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/31/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 12.9% stake in INVIVYD INC |
| 01/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2022 |
4
| Schmidt Peter (Chief Medical Officer) has filed a Form 4 on Invivyd, Inc.|
Txns:
| Granted 300,000 options to buy
@ $1.95, valued at
$585k
|
|
| 12/06/2022 |
3
| Schmidt Peter (Chief Medical Officer) has filed a Form 3 on Invivyd, Inc. |
| 12/06/2022 |
8-K
| Appointed COO|
Docs:
|
"FORM 8-K",
"Employment Agreement, by and between Invivyd, Inc. and Jeremy Gowler",
"INVIVYD APPOINTS JEREMY GOWLER AS CHIEF OPERATING AND COMMERCIAL OFFICER, PROMOTES PETE SCHMIDT, M.D., TO CHIEF MEDICAL OFFICER WALTHAM, MASS; December 06, 2022 - Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing from the..." |
|
|